CLAIMS

- 1. A method for generating insulin-secreting cells from precursor stem cells, said method comprising exposing said precursor cells to a nucleic acid molecule encoding neurogenin3 (ngn3) under conditions effective to generate said insulin-secreting cells from said precursor cells.
- 2. The method of claim 1, wherein the precursor cells are embryonic stem cells.
- 3. The method of claim 1, wherein said precursor cells are exposed <u>in vitro</u> to said nucleic acid molecule encoding ngn3.
- 4. A method for generating insulin-secreting cells from precursor stem cells, said method comprising exposing said precursor cells to an activator of ngn3 gene expression under conditions effective to generate said insulin-secreting cells from said precursor cells.
- 5. The method of claim 4, wherein said precursor cells are embryonic stem cells.
- 6. The method of claim 4, wherein said precursor cells are exposed <u>in vitro</u> to said activator of ngn3 gene expression.
- 7. A method for generating insulin-secreting cells from precursor stem cells, said method comprising exposing said precursor cells to a nucleic acid molecule encoding NeuroD/β2 under conditions effective to generate said insulin-secreting cells from said precursor cells.
- 8. The method of claim 7, wherein said precursor cells are embryonic stem cells.

- 9. The method of claim 7, wherein said precursor cells are exposed <u>in vitro</u> to said nucleic acid molecule encoding NeuroD/\(\beta\)2.
- 10. A method for generating insulin-secreting cells from precursor stem cells, said method comprising exposing said precursor cells to an activator of NeuroD/β2 gene expression under conditions effective to generate said insulin-secreting cells from said precursor cells.
- 11. The method of claim 10, wherein said precursor cells are embryonic stem cells.
- 12. The method of claim 10, wherein said precursor cells are exposed <u>in vitro</u> to said activator of NeuroD/β2 gene expression.
- 13. A method for generating insulin-secreting cells from adult pancreatic exocrine cells, said method comprising exposing said exocrine cells to a nucleic acid molecule encoding ngn3 under conditions effective to generate said insulin-secreting cells from said exocrine cells.
- 14. The method of claim 13, wherein said exocrine cells are pancreatic duct cells.
- 15. The method of claim 14, wherein said duct cells are human cells.
- 16. The method of claim 13, wherein said exocrine cells are exposed <u>in vitro</u> to said nucleic acid molecule encoding ngn3.
- 17. A method for generating insulin-secreting cells from adult pancreatic exocrine cells, said method comprising exposing said exocrine cells to an activator of ngn3 gene expression under conditions effective to generate said insulin-secreting cells from said exocrine cells.
- 18. The method of claim 17, wherein said exocrine cells are pancreatic duct cells.

THE ART OF THE TOTAL STREET, AND THE STREET, AND THE STREET, THE

- 19. The method of claim 18, wherein said duct cells are human cells.
- 20. The method of claim 17, wherein said exocrine cells are exposed <u>in vitro</u> to said activator of ngn3 gene expression.
- 21. A method for generating insulin-secreting cells from adult pancreatic exocrine cells, said method comprising exposing said exocrine cells to a nucleic acid molecule encoding NeuroD/β2 under conditions effective to generate said insulin-secreting cells from said exocrine cells
- 22. The method of claim 21, wherein said exocrine cells are pancreatic duct cells.
- 23. The method of claim 22, wherein said duct cells are human cells.
- 24. The method of claim 21, wherein said exocrine cells are exposed <u>in vitro</u> to said nucleic acid molecule encoding NeuroD/β2.
- 25. A method for generating insulin-secreting cells from adult pancreatic exocrine cells, said method comprising exposing said exocrine cells to an activator of NeuroD/β2 gene expression under conditions effective to generate said insulin-secreting cells from said exocrine cells.
- 26. The method of claim 25, wherein said exocrine cells are pancreatic duct cells.
- 27. The method of claim 26, wherein said duct cells are human cells.
- 28. The method of claim 25, wherein said exocrine cells are exposed <u>in vitro</u> to said activator of NeuroD/β2 gene expression.
- 29. An insulin-secreting cell produced by the method of claim 1.

- 30. An insulin-secreting cell produced by the method of claim 4.
- 31. An insulin-secreting cell produced by the method of claim 7.
- 32. An insulin-secreting cell produced by the method of claim 10.
- 33. An insulin-secreting cell produced by the method of claim 13.
- 34. An insulin-secreting cell produced by the method of claim 17.
- 35. An insulin-secreting cell produced by the method of claim 21.
- 36. An insulin-secreting cell produced by the method of claim 25.
- 37. A method for identifying whether a compound is an activator of ngn3 gene expression, said method comprising: (a) exposing progenitor stem cells or adult pancreatic exocrine cells to said compound in vitro and (b) measuring the generation of insulin-secreting cells from said exposed progenitor cells or adult pancreatic exocrine cells, where the generation of insulin-secreting cells from said exposed progenitor cells or adult pancreatic exocrine cells indicates that said compound is an activator of ngn3 gene expression.
- 38. A method for identifying whether a compound is an activator of NeuroD/β2 gene expression, said method comprising: (a) exposing progenitor stem cells or adult pancreatic exocrine cells to said compound <u>in vitro</u> and (b) measuring the generation of insulin-secreting cells from said exposed progenitor cells or adult pancreatic exocrine cells, where the generation of insulin-secreting cells from said exposed progenitor cells or adult pancreatic exocrine cells indicates that said compound is an activator of NeuroD/β2 gene expression.

on a literature for a sent includes confilerability in the property of the pro

- 39. A method for generating insulin-secreting cells from precursor stem cells or adult pancreatic exocrine cells, said method comprising exposing said cells to a compound identified by the method of claim 37 in an amount effective to generate said insulinsecreting cells.
- 40. A method for generating insulin-secreting cells from precursor stem cells or adult pancreatic exocrine cells, said method comprising exposing said cells to a compound identified by the method of claim 38 in an amount effective to generate said insulinsecreting cells.
- 41. An isolated insulin-secreting cell, wherein said cell is characterized by the absence of RNA transcripts for glucose transporter type 2 protein and by the presence of RNA transcripts for synaptophasin, chromogranin A, prohormone convertase PC1/3, and glucokinase.